Drug Name:
MICARDIS Rx

Generic Name and Formulations:
Telmisartan 20mg, 40mg, 80mg; tabs.
Company:
Boehringer Ingelheim Pharmaceuticals
Therapeutic Use:
Indications for MICARDIS:
Cardiovascular (CV) risk reduction in patients ≥55 years of age at high risk of developing major CV events who are unable to take ACE inhibitors.
Adult:
80mg once daily. Monitor BP; adjustments to meds that lower BP may be needed.
Children:
Not established.
Contraindications:
Concomitant aliskiren in patients with diabetes.
Boxed Warning:
Fetal toxicity.
Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting therapy or monitor closely. Severe CHF. Biliary obstruction. Hepatic or renal impairment. Renal artery stenosis. Dialysis (monitor for orthostatic hypotension). Neonates. Pregnancy: avoid. Nursing mothers: not recommended.
Pharmacological Class:
Angiotensin II receptor blocker (ARB).
Interactions:
See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May potentiate digoxin. Monitor lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted.
Adverse Reactions:
Back pain, upper respiratory tract infection, sinusitis, diarrhea, pharyngitis, angioedema; intermittent claudication, skin ulcer; rare: rhabdomyolysis.
How Supplied:
Tabs—3 x 10 (blister cards)
Indications for MICARDIS:
Hypertension.
Adult:
Individualized. Not volume-depleted: initially 40mg once daily; usual range 20–80mg/day. Salt/volume depleted: monitor closely or consider reduced dose. May add diuretic if insufficient response at 80mg/day.
Children:
Not established.
Contraindications:
Concomitant aliskiren in patients with diabetes.
Boxed Warning:
Fetal toxicity.
Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting therapy or monitor closely. Severe CHF. Biliary obstruction. Hepatic or renal impairment. Renal artery stenosis. Dialysis (monitor for orthostatic hypotension). Neonates. Pregnancy: avoid. Nursing mothers: not recommended.
Pharmacological Class:
Angiotensin II receptor blocker (ARB).
Interactions:
See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May potentiate digoxin. Monitor lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted.
Adverse Reactions:
Back pain, upper respiratory tract infection, sinusitis, diarrhea, pharyngitis, angioedema; rare: rhabdomyolysis.
How Supplied:
Tabs—3 x 10 (blister cards)
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Substitute for Lidocaine
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Identifying the Needs of Multidisciplinary Team Treating Geriatics Cancer Patients
- Hypofractionated Radiotherapy for Prostate Cancer: The New ASTRO/ASCO/AUA Guideline
- Risk of Hospitalization Remains High for Survivors of Childhood Leukemia
- Sequence of Immunotherapy, Targeted Therapy, Radiation Therapy Influences Overall Survival in Melanoma Brain Metastases
- Survey Demonstrates Implicit Bias Toward Cervical Cancer Diagnoses Among Nurses, Women
- Use of Watchful Waiting Up for Low-Risk Localized Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |